# | Aladdin ID | Assay Type | Description | Organism | Compounds | Reference | BAO Format | Source | |
---|---|---|---|---|---|---|---|---|---|
1. | ALA4418811 | B | Inhibition of C-terminal FLAG-6x-His epitope tagged and N-terminal human RAGE signal sequence tagged human BMP1 (121 to 721 amino acids) expressed in CHO-E1a cells pre-incubated for 10 mins before promyostatin peptide substrate addition and measured after 60 mins using 0.5 nM BMP1 by FRET based assay | Homo sapiens | 144 | cell-based format | Patent Bioactivity Data | ||
2. | ALA4418812 | B | Inhibition of C-terminal FLAG-6x-His epitope tagged and N-terminal human RAGE signal sequence tagged human BMP1 (121 to 721 amino acids) expressed in CHO-E1 cells pre-incubated for 10 mins before promyostatin peptide substrate addition and measured after 30 mins using 50 nM BMP1 by FRET based assay | Homo sapiens | 144 | cell-based format | Patent Bioactivity Data | ||
3. | ALA4418813 | B | Inhibition of recombinant human TLL1 I156V/N221S/V284A mutant expressed in CHOE1A cells pre-incubated for 10 mins before promyostatin peptide substrate addition and measured after 60 mins by FRET based assay | Homo sapiens | 140 | cell-based format | Patent Bioactivity Data | ||
4. | ALA4418814 | B | Inhibition of C-terminal Avi-6x-His epitope tagged and N-terminal human RAGE signal sequence tagged recombinant human TLL2 (26 to 1015 amino acids) expressed in CHOE1A cells incubated for 60 mins with promyostatin peptide substrate by FRET based assay | Homo sapiens | 138 | cell-based format | Patent Bioactivity Data | ||
5. | ALA4418817 | A | Drug metabolism in heparinized pooled human plasma at pH 7.5 assessed as formation of (3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl) furan-2-yl)phenyl)phosphonic acid at 100 to 2000 ng/ml incubated up to 4 or 24 hrs by by LC-MS/MS analysis | Homo sapiens | 36 | cell-free format | Patent Bioactivity Data | ||
6. | ALA4418824 | A | Drug metabolism in heparinized pooled human plasma at pH 7.5 assessed as conversion to active compound at 100 to 2000 ng/ml incubated for 4 by by LC-MS/MS analysis | Homo sapiens | 20 | cell-free format | Patent Bioactivity Data | ||
7. | ALA4418825 | P | Stability in pH 7.96 assessed as compound purity level at 1 mg/ml heated to 40 degC and measured at 200 hrs by LC/MS analsysis | 19 | small-molecule physicochemical format | Patent Bioactivity Data |